Intervention not reported
Mean FEV1 % predicted ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention leads to lower episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pneumocystis carinii pneumonia infection in children with cancer ‐ trimethoprim‐sulfamethoxazole prophylaxis only · children with cancers aged 12 years and under
The intervention probably leads to lower incidence of Pneumocystis carinii pneumonia infection in children… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention probably leads to lower mortality in children with HIV infection ‐ co‐trimoxazole… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ co‐trimoxazole prophylaxis only (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ isoniazid prophylaxis only (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pseudomonas infection in children with cystic fibrosis ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention showed no clear difference in incidence of Pseudomonas infection in children with cystic fibrosis… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
change in respiratory distress score at 30 minutes Scale from: 0 to 13. · patients with acute bronchiolitis in children up to three years of age
2 findings from 1 review
change in respiratory distress score at 30 minutes Scale from: 0 to 13. · patients with acute bronchiolitis in children up to three years of age
2 findings from 1 review
Intervention not reported
VT‐IPD, ITT (random) ( · Children under two years of age
The intervention leads to lower VT‐IPD, ITT (random) ( (high certainty).
1 finding from 1 review
Intervention not reported
All serotypes‐IPD, ITT (random) ( · Children under two years of age
The intervention leads to lower all serotypes‐IPD, ITT (random) ( (high certainty).
1 finding from 1 review
Intervention not reported
X‐ray defined pneumonia, ITT (random) ( · Children under two years of age
The intervention probably leads to lower X‐ray defined pneumonia, ITT (random) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical pneumonia, ITT (random) ( · Children under two years of age
The intervention probably leads to lower clinical pneumonia, ITT (random) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months · children 9 months to 15 years old
The intervention probably leads to higher self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort study (rate ratio) ‐ all ages · children 9 months to 15 years old
The intervention showed no clear difference in cohort study (rate ratio) ‐ all ages (low certainty).
1 finding from 1 review